Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

My confidence in this company remains, they should have a clear run to good profits from here on.
kim

kim
I agree not in but watching.

Hi. Just paid for moneyam L2 and decided to have a look at the threads. i wondered who was here (normally use another bb).

imo results good and the broker note is ultra conservative. very positive of a strong newsflow from here.

hambi

Is this end of BPRG (another Skyepharma) they seem to have given the market absolutely nothing and im watching my investment get smaller and smaller. Please change your name to Bio-goingbackwardsfasterthanJesonButton. how do these management people sleep at night??

Kivver, both BPRG and SEO are both under-achievers.

at least theres a chink of light with seo!!

If youve had a good day please consider giving a donation to the lads dressed as Elvis racing 350 miles to the North Pole on behalf of Great Ormond Street Hospital It makes the London Marathon seem like a stroll in the park!
To donate or view how theyre getting on visit
http://www.elvispolarchallenge.co.uk/
thanks for your time

Remember these, Maybe they are doing the right things.

For immediate release
25 April 2006

BioProgress signs sales and marketing partner for France

Cambridge, UK, 25 April 2006 - BioProgress (AIM: BPRG; NASDAQ: BPRG), the
specialty pharma and healthcare company, has signed a strategic partnership
agreement with the pharmaceutical sales and marketing company, Cristers, for
the promotion and distribution of its over-the-counter (OTC) SOLULEAVES
products in France.

The products that Cristers will market for BioProgress' subsidiary, Dexo S.A.
(Dexo) include the newly-launched Ronflux anti-snoring film strips, a range of
vitamin, mineral, nutritional and herbal products and a licensed range of
pharmaceutical OTC medicines. Each of these products uses BioProgress'
SOLULEAVES technology, in which active ingredients, colours and flavours are
incorporated into a GMO-free, non-animal derived film, which dissolves in the
mouth, releasing the active ingredients.

With over 160 sales personnel based in Herblay, near Paris, France, and
telemarketing and distribution systems in place, Cristers is well positioned to
sell Dexo products in France. The Company was formed in 2005 by Stephane Joly,
President of Cristers, with the backing of Investinov and Nepenthes. Investinov
is France's leading contract sales organisation with over 1200 medical
representatives. Nepenthes is one of France's largest retail pharmacist buying
groups with over 22% of the market share.

Richard Trevillion, CEO of BioProgress said: "This is an important strategic
partnership for BioProgress. Cristers has excellent credentials and will
provide Dexo with significant resources in the areas of pharmacy promotion,
direct marketing and promotion to doctors. With the backing of France's largest
contract sales organisation, and the largest pharmacist buying group, Cristers
will be able to rapidly expand the Dexo sales coverage in France. Our
confidence in the Cristers management team, has led us to commit to a long-term
strategic partnership."

BioProgress launched two of its SOLULEAVES products, Ronflux strips and
caffeine strips, via Dexo at Pharmagora 2006, an annual French retail
pharmacists' trade show, earlier this month. Due to the positive response to
these products at the show, BioProgress has accelerated its development and
launch programmes for all its SOLULEAVES products, to meet the anticipated
demand. These products are manufactured at the BioProgress group's cGMP
accredited facility based in Tampa, Florida, USA.

Short on FD resignation.

Perhaps things are beginnning to look up.

"BioProgress plc announces strategic joint development agreement with Uluru Inc.

Cambridge, UK, 4 May 2006 BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the
speciality pharma and healthcare company, today announced that it has signed a
joint strategic development agreement with the emerging speciality
pharmaceutical company, Uluru Inc. The companies will initially work together
to develop an anti-emetic product for the relief of nausea, using a combination
of BioProgress' film technology and Uluru's Oradisc drug delivery technology.
This relationship will then go on to develop further therapeutic products.

Uluru Inc. is focused on the development of a portfolio of wound management,
plastic surgery and oral care products to provide patients and consumers
improved clinical outcomes through controlled delivery. Uluru's OraDisc
technology is an innovative erodible film technology that sticks to mucous
membranes and allows sustained release of actives into the systemic
circulation over a period of several hours.

The new products are expected to resemble BioProgress' in-the-mouth range of
films strips, which can dissolve instantly, releasing the embedded active
ingredients. However, by adding the Oradisc technology to these films, the
resulting products will not only be fast acting, but will also offer sustained
release of actives over several hours. These new products will therefore have
properties that neither technology could achieve on its own.

Patients with nausea are often unable to take tablets effectively, so an
in-the-mouth instant release anti-emetic offers a good solution to treat acute
nausea and the OraDisc technology provides a longer term solution to the
problem. This is a therapeutic area with a large unmet need. BioProgress has a
large amount of in-house expertise in this area and Uluru has significant
experience in development of film technology through FDA approval.

Richard Trevillion, CEO of BioProgress, said: "We are delighted to be entering
a strategic partnership with Uluru Inc. The technologies from both companies
are complimentary and can work in combination to create products with both
instant release and sustained release characteristics. This approach has the
potential to create real therapeutic value and enhance the effectiveness of
medicines."

Kerry Gray, CEO of Uluru Inc. said: "This partnership is exciting for both
companies as we can access the development strengths and resources of both
groups. Our ability to combine instant release with sustained delivery over an
extended period has the potential to create considerable value. We will be
applying proven technologies to existing medicines with the objective of
dramatically improving the resultant profile."

+ + +

About BioProgress plc:
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the
company has over 80 patents granted or in application within 24 patent families
and has product development agreements and strategic alliances with several
global companies. As a virtually integrated business, BioProgress has acquired
sales and marketing resources within Europe and the US as a launch mechanism
for its own pharmaceutical products. The business continues to develop
innovative delivery mechanisms using its XGEL polymer technology, replacing
the need to use animal-derived gelatine in pharmaceutical and healthcare
products. For further information please go to
www.bioprogress.com


About Uluru Inc.:
Uluru Inc. is an emerging speciality pharmaceutical company focused on the
development of a portfolio of wound management plastic surgery and oral care
products to provide patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative transmucosal delivery system and
Hydrogel Nanoparticle aggregate technology.

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks, and uncertainties, including but not limited to statements made
relating to the establishment of a sales and marketing organization, the
marketing of three additional products and the achievement of a listing on
NASDAQ or an exchange. These statements are subject to numerous risks,
including but not limited to the risks detailed in the Company's Annual Report
on Form 10-K, for the year ended December 31, 2004, Quarterly Report on Form
10-Q for the quarter ended September 30, 2005 and other reports filed by us
with the Securities and Exchange Commission

For further information please contact:

BioProgress plc +44 (0) 1223 394250
Richard Trevillion, Chief Executive Officer

Northbank Communications +44 (0) 207 886 8150
Sue Charles
Gemma Bradley
Justine Lamond

A statement designed to stem the continuing fall in Bioprogress' share price failed to make an impact. The speciality pharmaceutical and healthcare company said that it remained confident of its prospects, confirming its expectation of further positive newsflow in the near term. The group put the recent decline in its share price down to the volatility in the wider market. However, the company has never attracted a significant degree of stability in its share price, so the recent swings are probably just as much company related Bioprogress related. Its shares finished the session 2p easier at 41p.

KD.

doe's anyone hold any rgt. good news today. buys are up.

Richard Trevellion is in the States this week, investors are expecting good news and a rising sp.

RT
18th May

The directors remain extremely confident in the prospects of the group and
anticipate further positive newsflow resulting from the continued
implementation of the Company's strategy, in the near term.

It's in the bag.

Be quick!

"The Company is already enjoying strong organic growth in all business areas and the
outlook for the remainder of this year is [ extremely] positive." (RT 12/04/2006) >

don't get bpgged down by the past. The last six months have seen massive restructuring. stable sp and great prospects

is anyone else here for the free L2?

doesn't look like it papa!

new website launch on monday

.

http://www.bioprogress.com/about